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Abstract
Background—There is considerable scientific interest in associations between protracted low-
dose exposure to ionizing radiation and the occurrence of specific types of cancer.
Methods—Associations between ionizing radiation and site-specific solid cancer mortality were 
examined among 308,297 nuclear workers employed in France, the United Kingdom, and the 
United States. Workers were monitored for external radiation exposure and follow-up 
encompassed 8.2 million person-years. Radiation–mortality associations were estimated using a 
maximum-likelihood method and using a Markov chain Monte Carlo method, the latter used to fit 
a hierarchical regression model to stabilize estimates of association.
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Results—The analysis included 17,957 deaths attributable to solid cancer, the most common 
being lung, prostate, and colon cancer. Using a maximum-likelihood method to quantify 
associations between radiation dose- and site-specific cancer, we obtained positive point estimates 
for oral, esophagus, stomach, colon, rectum, pancreas, peritoneum, larynx, lung, pleura, bone and 
connective tissue, skin, ovary, testis, and thyroid cancer; in addition, we obtained negative point 
estimates for cancer of the liver and gallbladder, prostate, bladder, kidney, and brain. Most of these 
estimated coefficients exhibited substantial imprecision. Employing a hierarchical model for 
stabilization had little impact on the estimated associations for the most commonly observed 
outcomes, but for less frequent cancer types, the stabilized estimates tended to take less extreme 
values and have greater precision than estimates obtained without such stabilization.
Conclusions—The results provide further evidence regarding associations between low-dose 
radiation exposure and cancer.
There is considerable scientific interest in associations between radiation dose and the 
occurrence of specific types of cancer.1–3 Such estimates have practical utility for decision 
makers, as well as scientific relevance for those interested in variation in associations 
between exposure to ionizing radiation and different types of cancer.
We report estimates of radiation dose–mortality associations derived using information from 
the International Nuclear Workers Study (INWORKS), a collaborative study of mortality 
among nuclear workers in France, the United Kingdom, and the United States. These 
workers were monitored for external exposure to radiation using personal dosimeters and 
have been followed over decades to collect information on vital status and causes of death. 
Using INWORKS data, we previously reported that the estimated excess relative rate per Gy 
for death attributable to solid cancer was 0.47 (90% CI = 0.18, 0.79).4,5 Here, we report on 
associations between ionizing radiation and site-specific solid cancer mortality. We employ a 
standard maximum-likelihood approach to fitting Poisson regression models to estimate 
radiation dose–mortality associations for specific types of cancer; we also employ a recently 
described hierarchical method for Poisson regression analysis to obtain stabilization of 
cause-specific estimates of association.6 The set of estimates derived using the latter 
approach complement the maximum-likelihood estimates and tend to have improved 
precision, less extreme values, and lower mean squared error than standard maximum-
likelihood estimates.6–9 In addition, the current paper examines associations between 
radiation dose and many site-specific cancers, some of which are relatively rare; this type of 
hierarchical regression analysis serves as an alternative to classical multiple-comparisons 
procedures and the resultant stabilized estimates may be of interest as an approach to 
identification of associations for further investigation.6,10,11
METHODS
We assembled data on workers from France, the United Kingdom, and the United States 
who were employed in the nuclear industry for at least 1 year and monitored for external 
radiation exposure through the use of personal dosimeters (Table 1). We obtained data from 
the Commissariat à l’Energie Atomique, AREVA Nuclear Cycle, and Electricité de France;
12
 from the National Registry for Radiation Workers which includes information from the 
Atomic Weapons Establishment, British Nuclear Fuels, Ltd, United Kingdom Atomic 
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Energy Authority, British Energy Generation, Magnox Electric, and Ministry of Defence;13 
and, from the US Department of Energy’s Hanford Site, Savannah River Site, Oak Ridge 
National Laboratory, and Idaho National Laboratory, as well as from the Portsmouth Naval 
Shipyard.14 In a previous report, we provided a fuller description of the study design and 
population.15
Monitoring data for exposure to ionizing radiation were available from company records for 
UK workers and government and company records for the United States and French 
workers, providing individual annual quantitative estimates of whole-body dose attributable 
to external penetrating radiation. We derived target organ doses by dividing recorded 
external penetrating radiation dose estimates by an organ-specific dose factor.16–18 Unless 
otherwise stated, any reference to dose in this paper implies estimated absorbed dose to a 
specified organ expressed in grays (Gy). Under most working conditions, absorbed doses 
from external exposures were accrued from exposures to photons of energies between 100 
and 3,000 keV, with a radiation weighting factor of 1.17 We used available records of 
estimated neutron doses, which were recorded in a unit of measure for equivalent dose (that 
is, rem or sievert), to construct categories of neutron monitoring status: whether a worker 
had a positive recorded neutron dose, and if so, whether their recorded neutron dose ever 
exceeded 10% of their total external radiation dose of record. We did not add recorded 
estimates of doses from tritium intakes to recorded estimates of dose attributable to external 
exposures. Available measures of incorporated radionuclides included positive bioassay 
results, indication of confirmed uptake, or an assigned committed dose. We grouped these 
measures as an indication of a known or suspected internal contamination. French and US 
workers with a known or suspected uptake were identified, as were UK workers who were 
known to have been monitored for internal exposure.
We ascertained vital status through 2004, 2001, and 2005 for the French, the UK, and the US 
cohorts, respectively, through linkage with death registries, employer records, and Social 
Security Administration records. Information on underlying cause of death was abstracted 
from death certificates and generally was coded according to the revision of the International 
Classification of Diseases (ICD) in effect at the time of death. We subdivided the broad 
category of all solid cancer mortality that we previously examined4 into site-specific 
cancers. The range of ICD codes associated with each cancer type examined is reported in 
Table 2.
A worker entered the study 1 year after the date of first employment or the date of first 
dosimetric monitoring, whichever was later. However, because in France, the national death 
registry provides individual information on causes of death only since 1968, French workers 
only enter follow-up on 1 January 1968 or later. A worker exited the study on the earliest of 
the following: date of death, date lost to follow-up, or end of follow-up.
Statistical Methods
We use the term cancer types to refer to deaths attributable to the specific types of solid 
cancer (Table 2). Letting j denote cancer type, and s index levels defined by the cross-
classification of covariates, a model for the cancer type–specific rates, λj, can be expressed 
as
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(expression 1)
where  is the cancer type–specific effects of covariates, Zj denotes target organ-specific 
cumulative dose in Gy, and β j quantifies the association between Zj and the jth cancer type 
as the excess relative rate (the relative rate minus 1) per Gy. The target organs selected for 
the cancer types that we examined are indicated in Table 3 and are similar to the target 
organs used in a prior analysis of site-specific cancer mortality in the Life Span Study of 
Japanese atomic bomb survivors (LSS).19
Maximum-likelihood Poisson Regression
For cancer type j, person-years at risk and deaths were tabulated by categories of the 
associated organ-specific cumulative dose and other study covariates. We fitted a Poisson 
regression model of the form shown in expression 1 for each cancer type20,21; an estimate of 
the coefficient of primary interest, βj, was adjusted to account for the effects of country, 
attained age (in 5-year intervals), sex, year of birth (in 10-year intervals), socioeconomic 
status (in five categories, based on job title, for French, US, and UK workers employed by 
the Atomic Energy Authority and Atomic Weapons Establishment; other UK workers were 
classified as nonmanual or manual skilled workers, based on employment category), 
duration of employment or radiation work (in 10-year intervals), and exposure to neutrons 
(whether a worker had a positive recorded neutron dose, and if so, whether their recorded 
neutron dose equivalent ever exceeded 10% of their total external radiation dose equivalent).
15,16
We report maximum-likelihood estimates of excess relative rate per Gy and associated 90% 
likelihood-based confidence intervals (CI), facilitating comparison of the precision of our 
estimated associations with findings reported in other important epidemiological studies of 
radiation-exposed populations.12,13,22–25 Expression 1 implies a constraint on βj to have a 
valid rate ratio (1 + β j Zj) ≥ 0.26 The constraint implies that , where max[Zj] 
is the maximum value for the organ-specific cumulative dose associated with cancer type j. 
If the lower bound of the likelihood-based confidence interval was not determined, then we 
indicate the lower bound as .
We lagged cumulative doses by 10 years to allow for an induction and latency period 
between exposure and death27; a 10-year lag was chosen to facilitate comparison of results 
with those from other studies of cancer mortality among nuclear workers.13,23 We undertook 
sensitivity analyses in which person-years at risk and deaths were classified with respect to 
cumulative dose lagged 5 or 15 years. For each cancer type, we compared results obtained 
under alternative lags with respect to goodness of model fit.28 To assess departures from 
linearity in the effect of cumulative dose, we fitted a model that included a higher order 
polynomial function of cumulative dose and evaluated the improvement in model goodness 
of fit. For select cancer types, the dose–response association was examined visually by 
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fitting a regression model with indicator variables for categories of cumulative dose and 
plotting the resultant relative rate estimates against category-specific mean dose values. We 
also undertook sensitivity analyses in which we restricted our analysis to male workers.
Hierarchical Poisson Regression Using Markov Chain Monte Carlo
We also obtained estimates of the β j parameters using a hierarchical approach to estimation 
of the regression model shown in expression 1, employing a form of the Poisson regression 
model in which the coefficients for the stratum-specific effects, , are not part of the 
expression for the likelihood.6,21 These estimates were obtained by joint modeling of the 
associations between organ-specific cumulative doses (lagged 10 years) and deaths 
attributable to the J cancer types using a tabulation of person-years at risk and deaths by 
cancer type, study covariates, and cumulative radiation dose. For each cell of this 
multidimensional person–time table, we calculated the person–time–weighted cell-specific 
mean dose to each of the target organs of interest. We employed a hierarchical regression 
model6 under which the distribution of the βj parameters is modeled as a function of the 
overall mean effect and residual effects:
(expression 2)
where δ is the prior mean and interpreted as the mean of the effects of exposure on the J 
cancer types, and τ2 is the prior variance that allows for deviation of the cancer-specific 
effect from a common mean effect. The model represents an assumption that, although 
radiosensitivity may differ by solid cancer type, a normal distribution of effects is a 
reasonable initial guess about the pattern of variation in associations by cancer type; 
however, the hierarchical modeling approach has sufficient flexibility to allow the cancer-
specific estimates to deviate from the mean if there is substantial evidence in the data to 
support it. A normal (0, 100) prior was specified for δ; a large variance was specified so that 
this prior was only weakly informative, thereby allowing the data to drive inference as much 
as possible. We performed a sensitivity analysis in which a normal (0.32, 5) prior was 
specific for δ, illustrating a more informative prior with a smaller variance and mean 
informed by an estimate of the excess relative rate per Gy for solid cancer mortality in a 
prior analysis of male survivors of the Japanese atomic bomb exposed at ages 20–60 years 
(excess relative rate per Gy = 0.32).23 Following recommendations regarding prior 
distributions for variance parameters in hierarchical models, we specified that the prior for 
the variance parameter, τ2, followed a uniform (0.01, 10) distribution.29
The degree to which the cancer-type–specific estimates are shrunk towards the common 
mean depends upon τ2. As τ2 approaches 0, the fitted exposure–response associations will 
be shrunk towards a common mean; when τ2 is large the cancer-type–specific estimates will 
be close to those obtained via estimation of associations one cancer type at a time.6,8,29 The 
parameter, τ2, was treated as an unknown parameter that was estimated.8,29 Estimates were 
obtained using a Markov chain Monte Carlo (MCMC) algorithm implemented in SAS 
PROC MCMC; the model was run for 100,000 iterations with the first 10,000 iterations 
discarded to allow for initial convergence. From MCMC samples, we derived cancer type–
Richardson et al. Page 5
Epidemiology. Author manuscript; available in PMC 2019 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
specific estimates of the excess relative rate per Gy, obtained as the mean of the posterior 
distribution and estimates of associated 90% highest posterior density credible intervals 
(CrI). Trace, auto-correlation function, and density plots were examined to assess 
convergence.30 Analyses were conducted using the EPICURE and SAS statistical packages.
20,31
RESULTS
The study includes 268,262 male workers and 40,035 female workers and encompasses 8.2 
million person-years of follow-up (Table 1). The mean year of birth for the US cohort is 
1934, whereas the mean years of birth for French and UK cohort members were 1947 and 
1944, respectively. The average age at the start of employment was 28 years; the average age 
at the end of follow-up was 58 years (Table 1).
There were 17,957 deaths attributable to solid cancer identified among the decedents, with 
the most common categories of solid cancer mortality being lung, prostate, colon, pancreas, 
and stomach cancer (Table 2). Overall, 83% of workers had a recorded dose >0 mGy. 
Among males, estimated average cumulative doses to the bladder, skin, colon, lung, and 
stomach were similar in magnitude, whereas estimated average cumulative doses to the liver, 
pancreas, and brain were slightly lower (Table 3). Among females, estimated average 
cumulative organ-specific doses were substantially lower than that among males, as females 
tended to have lower annual occupational radiation doses than males.16
Maximum-likelihood Poisson Regression Estimates
Positive estimates of the excess relative rate per Gy of cumulative dose, lagged by 10 years, 
were found for deaths attributable to oral, esophagus, stomach, colon, rectum, pancreas, 
peritoneum, larynx, lung, pleura, bone and connective tissue, skin, ovary, testis, and thyroid 
cancer. Negative estimates of the excess relative rate per Gy of cumulative dose, lagged by 
10 years, were found for deaths attributable to liver and gallbladder, prostate, bladder, 
kidney, and brain cancer. An estimate of excess relative rate per Gy was not obtained for 
cancer of the female breast or uterus as a consequence of the constraint on the parameter that 
quantifies the association between dose and these cancers (Table 4).
Associations for most cancers were smaller in magnitude under a 5-year lag, and model 
goodness of fit was similar to, or poorer than, that obtained under a 10-year lag assumption, 
with the exception of cancers of the stomach and testis for which the estimated radiation 
dose–mortality associations exhibited somewhat better goodness of fit under a 5-year than 
under a 10-year lag assumption (eTable 1; http://links.lww.com/EDE/B277). A 15-year lag 
assumption yielded better goodness of model fit for oral, colon, rectum, liver and 
gallbladder, pancreas, peritoneum, and ovary cancers than the fit obtained under a 10-year 
lag assumption.
A model describing a linear increase in the excess relative rate with dose appeared to 
provide a reasonable description of the data for cancers of the lung, colon, and prostate (the 
three leading cancer types) upon visual examination (Figure 1). To assess departure from 
linearity, we fitted a model that also included a parameter for the square of cumulative dose; 
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this led to very little improvement in the model goodness of fit for any cancer type, except 
thyroid cancer (likelihood ratio test statistic = 5.3; 1 degree of freedom; P = 0.02). In 
analyses restricted to males, maximum-likelihood point estimates and confidence intervals 
were very similar to those obtained for the full INWORKS cohort (eTable 2; http://
links.lww.com/EDE/B277).
Hierarchical Poisson Regression
Upon using a hierarchical model to stabilize estimates, none of the posterior mean estimates 
were negative, although posterior mean values for prostate, bladder, and liver cancer were 
relatively close to the null (Table 4). To facilitate convergence of the hierarchical model, 
parameters for associations between radiation dose and death attributable to breast and 
uterus cancer, cancer types that failed to converge in the maximum-likelihood model fittings 
and similarly exhibited poor model convergence in the MCMC models, were not estimated.
Estimates of radiation dose–mortality associations for specific cancer sites obtained using a 
hierarchical Poisson regression modeling approach showed less variability and tended to 
have less extreme values than those obtained by maximum-likelihood regression methods 
(Figure 2). For lung cancer, the most frequently observed specific cancer, the mean of the 
posterior distribution, and 90% CrI, for the association between radiation dose and lung 
cancer obtained by this hierarchical regression method, was similar to the point estimate and 
90% CI for the association between radiation dose and lung cancer obtained by maximum-
likelihood methods (Table 4). In contrast, for many of the less common cancer types, 
posterior mean estimates of the excess relative rate per Gy tended to have less extreme 
values and were stabilized substantially (as reflected by a much narrower 90% CrI than the 
90% CI). The estimated value of δ, the common mean effect of exposure on the cancer 
types, was 0.68 (90% CrI: 0.18, 1.17); the variance parameter, τ2, was estimated as 0.52 
(90% CrI: 0.01, 1.22). Diagnostic plots are provided as Supplemental Digital Content (http://
links.lww.com/EDE/B277). Analyses restricted to males yielded posterior central estimates 
and 90% CrIs very similar to those obtained for the full INWORKS cohort (eTable 2; http://
links.lww.com/EDE/B277), as did analyses conducted with a somewhat more informative 
prior for δ, a normal (0.32, 5) distribution (eTable 3; http://links.lww.com/EDE/B277).
DISCUSSION
We estimated dose–response associations for subcategories of solid cancer mortality among 
nuclear workers from France, the United Kingdom, and the United States. In a prior 
publication on the INWORKS cohort, we reported on analyses of radiation dose–mortality 
associations for all solid cancers aggregated together. That analysis combined different types 
of solid cancer into the broad category of all solid cancers.4 The observation of an 
association between exposure to ionizing radiation and a major category of cause of death, 
such as all solid cancers, is of interest for radiation protection and risk assessment. However, 
such an analysis does not allow inferences regarding effects of exposure on specific cancer 
types; implicit in such an analysis is the assumption that the effect size is similar from one 
cancer type to the next. In the current paper, we fitted maximum-likelihood Poisson 
regression models to derive cancer type–specific estimates of association for a number of 
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specific cancers. We also employed a hierarchical model to derive stabilized estimates of 
associations; this model allows that radiation–cancer type associations may vary from one 
cancer type to the next with parameters describing cancer type–specific associations 
modeled as following a normal distribution. The National Academy of Sciences’ BEIR VII 
committee noted that in analyses of the Japanese A-bomb survivors that variability in site-
specific radiation dose–cancer associations is generally consistent with random fluctuation 
around a common effect. Moreover, the approach employed here for modeling the 
parameters describing site-specific dose–response associations has been applied in previous 
analyses of radiation dose–cancer associations among atomic bomb survivors and other 
radiation-exposed populations, allowing for comparison of results and lending support for 
the appropach employed here.2,6,19 Simulations and theoretical work have shown that 
hierarchical models tend to be robust to moderate violations of the assumption of normality 
of effects.32–34 Posterior estimates for cancer-specific associations obtained from fitting a 
hierarchical model either tended to be similar to values obtained by fitting a separate model 
for each cancer type (e.g., lung cancer) or intermediate between the maximum-likelihood 
estimate for all solid cancers combined and the maximum-likelihood estimate for each 
cancer type obtained when fitting the models one cancer type at a time (Figure 2). Estimated 
associations for rare cancer types tended to be imprecise and were more impacted by the use 
of a hierarchical model for stabilization than common outcomes. This is consistent with 
expectation for this type of approach, in which the ensemble of estimates is stabilized and 
may tend to have reduced mean squared error.
The results of our hierarchical modeling are interesting to compare to a similar analysis 
conducted using data from the Life Span Study (LSS) of atomic bomb survivors.6 Estimates 
of excess relative rate per Gy for cancer of the lung, prostate, and colon (the most common 
cancers in INWORKS) from our hierarchical regression analysis [0.56 (90% CrI = 0.08, 
1.02), 0.25 (90% CrI = −0.38, 0.87), and 0.42 (90% CrI = −0.32, 1.13), respectively] were 
slightly lower than estimates from a hierarchical regression analysis of the LSS [0.67 (95% 
CrI = 0.44, 0.92); 0.33 (95% CrI = −0.11, 0.76); and 0.49 (95% CrI = 0.28, 0.69), 
respectively].6 Among other leading cancers in INWORKS, posterior estimates of the excess 
relative rate per Gy from INWORKS [for cancer of the pancreas 0.50 (90% CrI = −0.37, 
1.34), for stomach 0.88 (90% CrI = 0.01, 1.82), and for esophagus 0.83 (90% CrI = −0.06, 
1.77)] were somewhat larger than estimates from the LSS (pancreas 0.42 [95% CrI = 0.09, 
0.78]; stomach 0.33 [95% CrI = 0.22, 0.44], and esophagus 0.56 [95% CrI = 0.17, 0.97]).6 
Lung cancer was among the sites with the largest hierarchically adjusted magnitudes of 
association, which is consistent with other studies that suggest lung cancer to be relatively 
radiosensitive, whereas sites such as prostate tend to be among the sites with the smallest 
adjusted estimates of association, again consistent with other studies. However, there are 
exceptions as well. For example, some other studies suggest relatively weak associations 
between radiation and cancers of the oral cavity and rectum, although our results included 
these among the most positive.
INWORKS relies upon death certificate information for classification of workers with 
respect to the occurrence of cancer; consequently, one potential source of bias in our 
estimates of occupational exposure–mortality associations relates to outcome 
misclassification.35 The sensitivity and specificity of the death certificate as a tool for 
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ascertaining cancer occurrence is imperfect and varies by cancer type36; therefore, variation 
in the estimated associations by cancer type could reflect outcome misclassification. Prior 
work suggests that estimates of the rate ratio were relatively insensitive to changes in 
hypothetical values of sensitivity but changed substantially when specificity was altered, 
although impact tended to be modest under plausible values of sensitivity and specificity.
35,37
 Empirical studies of the accuracy of death certificate–based cancer ascertainments 
suggest very high levels of specificity (>99%) for classifications based upon underlying 
cause of death information for most site-specific cancers, implying minimal potential for 
outcome misclassification to be a major source of bias in our cancer type–specific estimates 
of excess relative rate per Gy.36,38,39 Bias also may occur attributable to errors in dose 
estimation, generally expected to be nondifferential with respect to the outcomes under 
investigation. Substantial work has been done to characterize, and account for, the 
performance of the historical dosimeters used by the workers from France, the United 
Kingdom, and the United States included in INWORKS.16–18 Prior work involving 
sensitivity analyses has suggested that radiation risk estimates based on doses quantified by 
individual dosimeters are not substantially impacted under a range of assumptions about 
factors that may lead to measurement error in dose.40 Nonetheless, limitations in dose 
estimation, particularly as related to internal depositions and neutrons, remain a potential 
source of bias; in prior analyses of solid cancer mortality in the INWORKS cohort, analyses 
that excluded workers ever flagged for incorporated radionuclides or internal monitoring led 
to a modest increase in the estimated excess relative rate per Gy.4 Variation in the estimated 
associations by cancer type may also be impacted by patterns of confounding that differ by 
cancer type. Although we adjusted for country-specific variation in age, sex, birth cohort, 
and socioeconomic status in our models for cancer site–specific rates, there remains 
potential for residual confounding of site-specific associations. For example, there is 
potential for residual confounding attributable to differences between facilities within 
country in factors associated with mortality and exposure. In prior analyses, we undertook a 
sensitivity analysis to assess potential confounding by differences (other than external 
radiation doses) between the major employers in each country; to do this, we fitted a model 
that adjusted for each of the main facilities included in INWORKS and observed that there 
was little evidence of residual confounding by facility.4 Consideration of potential 
confounders depends, in part upon, the outcome examined. For example, smoking, which 
was unmeasured in our study, may be an important confounder in analyses of lung cancer, a 
somewhat less important confounder in analyses of other smoking-related cancers and of 
little consequence as a confounder in analyses of cancers that have little or no association 
with smoking. Contrary to the pattern that would be expected if there was confounding by 
smoking, we noted previously that the magnitude of the estimated excess relative rate per Gy 
of solid cancer was essentially unchanged upon excluding lung cancer4; moreover, we 
previously noted the lack of association between radiation dose and chronic obstructive 
pulmonary disease,4 an outcome strongly associated with smoking.41 Asbestos is a potential 
confounder of the radiation–lung cancer association, and we lack individual information on 
asbestos exposure. We examined the association between radiation and cancer of pleura and 
mesothelioma and observed a positive, albeit imprecise, association. In a prior analysis, we 
observed that the association between radiation dose and mortality attributable to all solid 
cancers other than lung and pleura cancer was positive (excess relative rate = 0.43 per Gy; 
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90% CI = 0.08 to 0.82) and similar in magnitude to the point estimate obtained for all solid 
cancers.4
Studies of nuclear workers have the potential to improve knowledge on health effects 
associated with low dose and low dose rate radiation exposure. Follow-up of large cohorts of 
nuclear industry workers has been ongoing for over 3 decades. Further work on the 
development of informative prior distributions could be useful in strengthening 
understanding of site-specific radiation dose–cancer associations. In addition, as follow-up 
of cohorts included in INWORKS continue to be updated, the information available from 
international pooling of these data should offer even more useful insights into the risks of 
cancer from protracted low-dose rate exposure to ionizing radiation.
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FIGURE 1. 
Relative rate of cancer site–specific mortality by categories of cumulative dose, lagged 10 
years in INWORKS. Gray lines indicate 90% confidence intervals, and the dashed line 
depicts the fitted linear model for the change in the excess relative rate of mortality with 
dose. A. Lung cancer. B. Colon cancer. C. Prostate cancer.
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FIGURE 2. 
Maximum-likelihood and hierarchical regression estimates of excess relative rate per Gy 
cumulative organ-specific dose (10-year lag assumption) for death attributable to specific 
cancer categories. INWORKS consortium, 1944–2005. Circles indicate cancer site–specific 
hierarchical regression estimates. Diamonds indicate cancer site–specific maximum-
likelihood estimates. Whiskers indicate 90% credible intervals for hierarchical regression 
estimates and 90% confidence intervals for maximum-likelihood estimates; if a lower bound 
was not determined, the plotted point indicates only the upper confidence bound. Gray 
dashed line indicates estimated mean of hierarchical regression estimates. The maximum-
likelihood estimate for cancer of the testis (32.55 per Gy) was not plotted because it was 
outside the range of the plotted data.
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TABLE 1
Characteristics of INWORKS Cohorts
France United Kingdom United States INWORKS
No. workers 59,003 147,866 101,428 308,297
 Males 51,567 134,812 81,883 268,262
 Females 7,436 13,054 19,545 40,035
Calendar year of birth
 Mean (SD) 1947 (13) 1944 (18) 1934 (17) 1941 (18)
 Range 1894–1975 1877–1983 1873–1973 1873–1983
Age at start employment (years)
 Mean (SD) 27 (7) 28 (11) 30 (9) 28 (10)
Age at last observation (years)
 Mean (SD) 56 (13) 54 (15) 65 (13) 58 (15)
Duration of employment (years)
 Mean (SD) 21 (10) 13 (10) 14 (11) 15 (11)
Calendar years of follow-up
 Range 1968–2004 1946–2001 1944–2005 1944–2005
Duration of follow-up (years)
 Mean (SD) 25 (9) 23 (12) 33 (13) 27 (12)
Vital status
 Alive 52,565 118,775 65,573 236,913
 Deceased 6,310 25,307 35,015 66,632
 Emigrated or lost to follow-up 128 3,784 840 4,752
Person-years (millions) 1.5 3.4 3.3 8.2
SD, standard deviation.
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TABLE 2
Solid Cancer Deaths Among Workers Included in the INWORKS Consortium (Nuclear Workers in France, 
United Kingdom, and United States), 1944–2005
France United Kingdom United States INWORKS
Deaths (ICD-9 codes)
 Solid cancer (140–199) 2,356 6,994 8,607 17,957
 Oral (140–149) 109 100 150 359
 Esophagus (150) 92 329 226 647
 Stomach (151) 99 542 263 904
 Colon (152–153) 172 542 856 1,570
 Rectum (154) 61 313 165 539
 Liver and gallbladder (155–156) 132 115 206 453
 Pancreas (157) 139 325 512 976
 Peritoneum (158–159) 47 67 31 145
 Larynx (161) 57 63 65 185
 Lung (162) 595 2,244 2,963 5,802
 Pleura (163) and mesotheliomaa 48 133 92 273
 Bone and connective (170–171) 21 44 76 141
 Skin (172–173) 51 102 216 369
 Female breast (174) 70 67 246 383
 Uterus (179–182) 16 21 34 71
 Ovary (183) 21 22 79 122
 Prostate (185) 149 630 906 1,685
 Testis (186) 8 28 12 48
 Bladder (188, 189.3–189.9) 56 273 250 579
 Kidney (189.0–189.2) 70 174 247 491
 Brain (191–192) 84 227 283 594
 Thyroid (193) 6 16 16 38
 Remainder (160, 164–165, 175, 184, 187, 190, 194–199) 253 617 713 1,583
a
ICD-10 code C45.
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